Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

被引：0

作者：

Gumuzio, Juan

Calleja, Veronique

Miles, James

Sancehz-Magraner, Lissete

Aguirre, Fernando

机构：

来源：

MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期

关键词：

D O I：

10.1158/1535-7163.TARG-23-A124

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A124

引用

页数：2

共 50 条

[1] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Bocanegra, Ana
Blanco, Ester
Fernandez-Hinojal, Gonzalo
Arasanz, Hugo
Chocarro, Luisa
Zuazo, Miren
Morente, Pilar
Vera, Ruth
Escors, David
Kochan, Grazyna
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
[2] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
Lin, Heng
Wei, Shuang
Vatan, Linda
Kryczek, Ilona
Zou, Weiping
JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
[3] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, Jie
Gao, Zhitao
Li, Xiang
Dong, Liang
Han, Weidong
Nie, Jing
ONCOTARGET, 2017, 8 (66) : 110693 - 110707
[4] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning, Melanie
Kobus, Franca
Babayan, Anna
Wikman, Harriet
Velthaus, Janna-Lisa
Bergmann, Sonja
Schatz, Stefanie
Falk, Markus
Berger, Lars-Arne
Boettcher, Lisa-Marie
Paesler, Sarina
Gorges, Tobias M.
O'Flaherty, Linda
Hille, Claudia
Joosse, Simon A.
Simon, Ronald
Tiemann, Markus
Bokemeyer, Carsten
Reck, Martin
Riethdorf, Sabine
Pantel, Klaus
Loges, Sonja
CANCERS, 2019, 11 (06):
[5] Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1
Darabi, Sourat
Braxton, David R.
Eisenberg, Burton L.
Demeure, Michael J.
ONCOLOGY-NEW YORK, 2020, 34 (08): : 321 - 327
[6] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
Liu, Y.
Cao, L.
Che, X.
Qiu, X.
Li, Z.
Yang, B.
Wang, S.
Qu, X.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
[7] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
Guo, Jiazheng
Yu, Fengyi
Zhang, Kuojun
Jiang, Sheng
Zhang, Xiangyu
Wang, Tianyu
RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
[8] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, Jinhua
Chen, Zichao
Li, Yaqun
Zhao, Wenjie
Wu, JiBiao
Zhang, Zhen
FRONTIERS IN PHARMACOLOGY, 2021, 12
[9] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
Monneur, Audrey
Goncalves, Anthony
Bertucci, Francois
BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
[10] Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, Laurence P.
Hsueh, Eddy C.
BIOMARKER RESEARCH, 2017, 5

← 1 2 3 4 5 →

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (&lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment